Alkermes
E148148
Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Alkermes canonical | 1 |
| Alkermes Pharma Ireland Limited | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1172193 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alkermes Context triple: [Vumerity, developedBy, Alkermes]
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Alkermes Target entity description: Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
-
C.
Novartis
Novartis is a global Swiss-based pharmaceutical company known for developing innovative medicines across a wide range of therapeutic areas.
-
D.
Elan Pharmaceuticals
Elan Pharmaceuticals was a biotechnology company best known for developing therapies for neurological and autoimmune diseases, including the multiple sclerosis drug Tysabri.
-
E.
Lonza
Lonza is a global Swiss-based life sciences company specializing in pharmaceutical, biotech, and nutrition products and services, particularly in contract development and manufacturing.
- F. None of above. chosen
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
biopharmaceutical company
ⓘ
public company ⓘ |
| businessModel |
partnership-based drug development
ⓘ
research and development of proprietary medicines ⓘ |
| chairman | Richard Pops ⓘ |
| chiefExecutiveOfficer | Richard Pops ⓘ |
| collaboratesWith | major pharmaceutical companies ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| develops |
biologic therapies
ⓘ
small-molecule drugs ⓘ |
| focusesOn |
central nervous system disorders
ⓘ
serious chronic diseases ⓘ |
| foundedBy |
Michael Wall
ⓘ
Richard Pops ⓘ |
| hasManufacturingFacility |
Athlone
ⓘ
surface form:
Athlone, Ireland
Wilmington, Ohio ⓘ |
| hasOperationalHeadquarters | Waltham, Massachusetts NERFINISHED ⓘ |
| hasSubsidiary |
Alkermes
self-linksurface differs
ⓘ
surface form:
Alkermes Pharma Ireland Limited
|
| headquartersCountry | Ireland ⓘ |
| headquartersLocation | Dublin ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| listedOn |
Nasdaq Global Select Market
ⓘ
surface form:
NASDAQ Global Select Market
|
| product |
Aristada
ⓘ
Aristada ⓘ
surface form:
Aristada Initio
Vivitrol ⓘ |
| regionServed | global ⓘ |
| regulatoryEnvironment |
EMA-regulated
ⓘ
FDA-regulated ⓘ |
| researchFocus |
immuno-oncology
ⓘ
neuroscience ⓘ |
| specializesIn |
drug delivery technologies
ⓘ
long-acting injectable formulations ⓘ |
| stockExchange | NASDAQ ⓘ |
| targetPatientGroup |
patients with addiction disorders
ⓘ
patients with psychiatric disorders ⓘ |
| therapeuticArea |
alcohol dependence
ⓘ
bipolar disorder ⓘ major depressive disorder ⓘ opioid dependence ⓘ schizophrenia ⓘ |
| tickerSymbol | ALKS ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Alkermes Description of subject: Alkermes is a biopharmaceutical company that develops innovative medicines for central nervous system disorders and other serious chronic diseases.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Alkermes Pharma Ireland Limited